Anatomic distribution of [18F] fluorodeoxyglucose-avid lymph nodes ...

52 H.P. Fontanilla et al Practical Radiation Oncology: January-March 2013patients who are at higher risk of nodal involvement inthese regions.Our study had several limitations. Although thespecificity of PET/CT in the detection of LN metastasesfrom cervical cancer is 95% in a pooled meta-analysis,there is a considerable range in the published sensitivitiesand specificities of PET/CT in detecting pelvic lymphnodes. 13,14,22-29 Without pathologic evidence we cannotbe certain that all of the mapped LNs contained metastases.Furthermore, because these FDG-avid nodes were grosslyenlarged, we cannot be certain what constitutes adequatecoverage for nonenlarged LNs with micrometastaticdisease. We attempted to minimize the impact of LNvolume by evaluating each LN as a 1-cm sphere expandedfrom LN center for analysis of treatment coverage. Thepresence of grossly enlarged LNs may also affect lymphaticdrainage in unpredictable ways. Our evaluation ofcoverage by RTOG contours is limited because thesecontours were intended for use in postoperative treatmentand not for patients with grossly positive LNs; the RTOGalso recommends that any suspicious LNs should beincluded in the contours. Despite these limitations, webelieve that our study extends the understanding of thenodal regions at highest risk for metastasis from cervicalcancer. Considering the significant overlap that weobserved in regions of involved LNs, even for patientswith only a few positive LNs, these areas with high rates ofLN positivity likely indicate the typical drainage patternin patients with cervical cancer.ConclusionsUnderstanding the anatomic location of PET-positiveLNs in cervical cancer is useful for identifying nodalregions at particular risk of harboring metastatic disease.The probability map we created can help define targets forconformal radiation therapy and guide changes inconventional radiation therapy techniques. The externaliliac and common iliac nodal regions had particularly highnumbers of positive LNs, and thus these areas requiregenerous coverage, especially between the vasculature andthe psoas muscle.References1. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrentchemotherapy versus pelvic and para-aortic irradiation for high-riskcervical cancer: an update of Radiation Therapy Oncology Grouptrial (RTOG) 90-01. J Clin Oncol. 2004;22:872-880.2. Landoni F, Maneo A, Colombo A, et al. Randomised study of radicalsurgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet.1997;350:535-540.3. Beadle BM, Jhingran A, Yom SS, Ramirez PT, Eifel PJ. Patterns ofregional recurrence after definitive radiotherapy for cervical cancer.Int J Radiat Oncol Biol Phys. 2010;76:1396-1403.4. Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B.Dosimetric comparison of bone marrow-sparing intensity-modulatedradiotherapy versus conventional techniques for treatment of cervicalcancer. Int J Radiat Oncol Biol Phys. 2008;71:1504-1510.5. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, MundtAJ. Intensity-modulated whole pelvic radiation therapy in patientswith gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2000;48:1613-1621.6. Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensitymodulatedradiation therapy (IMRT) reduces small bowel, rectum,and bladder doses in patients with cervical cancer receiving pelvicand para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261-266.7. Benedetti-Panici P, Maneschi F, Scambia G, et al. Lymphatic spreadof cervical cancer: an anatomical and pathological study based on225 radical hysterectomies with systematic pelvic and aorticlymphadenectomy. Gynecol Oncol. 1996;62:19-24.8. Marnitz S, Köhler C, Bongardt S, et al. Topographic distribution ofsentinel lymph nodes in patients with cervical cancer. GynecolOncol. 2006;103:35-44.9. Dinniwell R, Chan P, Czarnota G, et al. Pelvic lymph nodetopography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J RadiatOncol Biol Phys. 2009;74:844-851.10. Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelviclymph nodes: guidelines for delineation in intensity-modulatedradiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:1604-1612.11. Plentl AA, Friedman EA. Lymphatic system of the female genitalia.The morphologic basis of oncologic diagnosis and therapy. MajorProbl Obstet Gynecol. 1971;2:1-223.12. Mangan CE, Rubin SC, Rabin DS, Mikuta JJ. Lymph nodenomenclature in gynecologic oncology. Gynecol Oncol. 1986;23:222-226.13. Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performanceof computer tomography, magnetic resonance imaging, andpositron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes inpatients with cervical cancer: meta-analysis. Cancer Sci. 2010;101:1471-1479.14. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging bypositron emission tomography in patients with carcinoma of thecervix. J Clin Oncol. 2001;19:3745-3749.15. Small WJ, Mundt AJ. Consensus guidelines for the delineation of theintensity modulated pelvic radiotherapy CTV in the postoperativetreatment of endometrial and cervical cancer. Available at: http://www.rtog.org/CoreLab/ContouringAtlases/GYN.aspx. AccessedMarch 1, 2011.16. Small WJ, Mell LK, Anderson P, et al. Consensus guidelines fordelineation of clinical target volume for intensity-modulated pelvicradiotherapy in postoperative treatment of endometrial and cervicalcancer. Int J Radiat Oncol Biol Phys. 2008;71:428-434.17. Lim K, Small Jr W, Portelance L, et al. Consensus guidelines fordelineation of clinical target volume for intensity-modulated pelvicradiotherapy for the definitive treatment of cervix cancer. Int JRadiat Oncol Biol Phys. 2011;79:348-355.18. Wang H, Dong L, O'Daniel J, et al. Validation of an accelerated‘demons’ algorithm for deformable image registration in radiationtherapy. Phys Med Biol. 2005;50:2887-2905.19. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases frompelvic tumors: anatomic classification, characterization, and staging.Radiology. 2010;254:31-46.20. Small Jr W, Mell LK, Anderson P, et al. Consensus guidelines fordelineation of clinical target volume for intensity-modulated pelvicradiotherapy in postoperative treatment of endometrial and cervicalcancer. Int J Radiat Oncol Biol Phys. 2008;71:428-434.21. Levenback C, Coleman RL, Burke TW, et al. Lymphatic mappingand sentinel node identification in patients with cervix cancer